References
- Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021 Aug 2;23(8):1231–1251.
- Low JT, Ostrom QT, Cioffi G, et al. Primary brain and other central nervous system tumors in the United States (2014–2018): a summary of the CBTRUS statistical report for clinicians. Neurooncol Pract. 2022 May;9(3):165–182.
- Williams EA, Santagata S, Wakimoto H, et al. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic. Acta Neuropathol Commun. 2020 Oct 21;8(1):171.
- Mawrin C, Perry A. Pathological classification and molecular genetics of meningiomas. J Neurooncol. 2010 Sep;99(3):379–391.
- Kaur G, Sayegh ET, Larson A, et al. Adjuvant radiotherapy for atypical and malignant meningiomas: a systematic review. Neuro Oncol. 2014 May;16(5):628–636.
- Nabors LB, Portnow J, Ahluwalia M, et al. Central nervous system cancers, Version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020 Nov 2;18(11):1537–1570.
- Ji Y, Rankin C, Grunberg S, et al. Double-blind Phase III randomized trial of the antiprogestin agent mifepristone in the treatment of unresectable meningioma: SWOG S9005. J Clin Oncol. 2015 Dec 1;33(34):4093–4098.
- Goodwin JW, Crowley J, Eyre HJ, et al. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol. 1993 Jan;15(1):75–77.
- Moazzam AA, Wagle N, Zada G. Recent developments in chemotherapy for meningiomas: a review. Neurosurg Focus. 2013 Dec;35(6):E18.
- Chamberlain MC. Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma. J Neurooncol. 2012 Apr;107(2):315–321.
- Graillon T, Tabouret E, Chinot O. Chemotherapy and targeted therapies for meningiomas: what is the evidence? Curr Opin Neurol. 2021 Dec 1;34(6):857–867.
- Chamberlain MC, Glantz MJ, Fadul CE. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology. 2007 Sep 4;69(10):969–973.
- Simo M, Argyriou AA, Macia M, et al. Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy. Cancer Chemother Pharmacol. 2014 May;73(5):919–923.
- Norden AD, Ligon KL, Hammond SN, et al. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology. 2015 Jan 20;84(3):280–286.
- Goldbrunner R, Stavrinou P, Jenkinson MD, et al. EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 2021 Nov 2;23(11):1821–1834.
- Le Rhun E, Taillibert S, Chamberlain MC. Systemic therapy for recurrent meningioma. Expert Rev Neurother. 2016 Aug;16(8):889–901.
- Kaley TJ, Wen P, Schiff D, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015 Jan;17(1):116–121.